Table 1.
Baseline demographics and clinical characteristics (safety analysis set)
| Patients with malignant lymphoma (N = 51) |
|
|---|---|
| Sex (male) | 34 (66.7) |
| Age (years), median (min, max) | 54.0 (38, 72) |
| ≥ 65 years, n (%) | 15 (29.4) |
| Height (cm), median (min, max) | 167.1 (150.9, 185.1) |
| Weight (kg), median (min, max) | 62.9 (36.3, 95.1) |
| BSA (m2)a, median (min, max) | 1.7 (1.3, 2.1) |
| ECOG PS | |
| 0 | 30 (58.8) |
| 1 | 18 (35.3) |
| 2 | 3 (5.9) |
| Disease type | |
| New onset | 27 (52.9) |
| Relapse | 24 (47.1) |
| Prior HSCT transplantations | |
| 0 | 48 (94.1) |
| 1 | 3 (5.9) |
| Complicationsb | 48 (94.1) |
| Constipation | 24 (47.1) |
| Hypertension | 11 (21.6) |
| Insomnia | 10 (19.6) |
| Neuropathy peripheral | 10 (19.6) |
| Hyperlipidemia | 6 (11.8) |
All patients were Asian. Number of patients (%) are shown unless otherwise indicated
BSA body surface area, ECOG PS Eastern Cooperative Oncology Group performance status, HSCT hematopoietic stem cell transplantation
aCalculated using DuBois formula [15]: weight (kg)0.425 × height (cm)0.725 × 0.007184
bComplications occurring in ≥ 10% of patients are shown